Kazia Therapeutics Limited (KZIA) delivered a return of 45.86% over the past year. Since KZIA does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Kazia Therapeutics Limited one year ago would be worth $14,586 today, representing a gain of $4,586.

Kazia Therapeutics Limited (KZIA) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For KZIA, the total return equals the price-only return.

Yes, Kazia Therapeutics Limited (KZIA) outperformed the S&P 500 by 23.01 percentage points over the past year. KZIA delivered a total return of 45.86%, compared to the S&P 500's 22.86%. This 23.01pp alpha means investors in KZIA earned more than a passive S&P 500 index fund.

Kazia Therapeutics Limited (KZIA) experienced a maximum drawdown of -68.19% over the past year, declining from its peak on 2025-12-08 to its trough on 2026-01-02. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Kazia Therapeutics Limited (KZIA)'s long-term returns with dividends reinvested. Over 10 years, the total return is -96.5% (-28.5% CAGR) — $10,000 would have grown to $350. Over 20 years: -99.5% total return (-23.7% CAGR) — $10,000 → $45. Over 30 years: -99.5% total return (-16.0% CAGR) — $10,000 → $54. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Kazia Therapeutics Limited's best calendar year was 2012 with a total return of 152.7%. Its worst year was 2022 with a total return of -92.8%. This range shows the volatility investors should expect — the difference between the best and worst year is 245.5 percentage points.